DENTSPLY SIRONA, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Cherny from Leerink Partners maintained a Hold rating on the stock and has a $17.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Cherny has given his Hold rating due to a combination of factors affecting DENTSPLY SIRONA’s performance. Despite the company’s profitability slightly surpassing expectations, sales growth remains under pressure, particularly due to the impact of Byte. Even when excluding Byte, organic growth showed a decline, with equipment and orthodontic/implant segments leading this downturn, although the consumables business showed some resilience.
Additionally, the unchanged guidance for FY25 appears reasonable in light of the previous quarter’s adjustments and the arrival of new management. The focus is now on how the new leadership will enhance performance and their perspective on the company’s position in a challenging market. These strategic factors, rather than the recent results, are likely to influence the stock’s future trajectory.
In another report released yesterday, Evercore ISI also maintained a Hold rating on the stock with a $17.00 price target.